Furthermore, combination therapy with AT/DT-NE#E (oral MCT) and anti-PD1 (IP) resulted in tumor volume reductions that were 306%, 265%, and 226% greater than those observed with AT/DT (IV), AT/DT-NE#E (oral monotherapy), and anti-PD1 (monotherapy), respectively (Figure 5a,b). The gene discussed is PDCD1; the disease is neoplasm.